Hangzhou Capital-backed BrainCo, ChengTian Tech rank in 2026 Future Healthcare 100 list

  • Hangzhou State Capital Investment and Operations reported multiple direct-investment portfolio companies ranked in the “2026 Future Healthcare 100” lists.
  • Innovation devices, intelligent manufacturing Top 100: BrainCo; ChengTian Technology.
  • Innovative drugs, biologics Top 100: Qihan Bio; Linke Pharma; Haichang Bio; Triastek; Kejun Pharma; Lingyi Bio.
  • Health services, industry-chain services Top 100: Ailios; Heiyu Science.
  • Other invested companies cited in the sector: Deepwise AI Lab; Yangli Pharma; Nurotron; I-Mab; Yuyan Pharma.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hangzhou State Capital Investment and Operations Co Ltd published the original content used to generate this news brief on June 01, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.